반려동물 건강 관리 시장 예측(-2034년) : 제품 유형, 동물종, 치료 영역, 진단 방법, 투여 경로, 용도, 최종사용자, 유통 채널 및 지역별 분석

According to Stratistics MRC, the Global Pet Healthcare Market is accounted for $144.2 billion in 2026 and is expected to reach $257.2 billion by 2034 growing at a CAGR of 7.5% during the forecast period. Pet healthcare encompasses products, services, and technologies designed to maintain and improve the health and well-being of companion animals, including pharmaceuticals, vaccines, diagnostic products, therapeutic devices, and healthcare services. The market covers various routes of administration including oral, injectable, topical, transdermal, and other methods across applications including preventive care, disease diagnosis, disease treatment, wellness management, and rehabilitation and recovery. Growing pet ownership, increasing humanization of pets, rising expenditure on pet health, and expanding veterinary services are key drivers of market expansion across all regions.

Market Dynamics:

Driver:

Increasing pet ownership and humanization of pets

The rising global pet population and growing trend of treating pets as family members are primary drivers for the pet healthcare market. Pet owners are increasingly investing in preventive care, advanced diagnostics, and treatment options that mirror human healthcare standards. The humanization of pets has led to greater awareness of health issues, increased veterinary visits, and higher willingness to spend on medical care. Millennials and Gen Z pet owners, in particular, prioritize pet health and wellness. As pet ownership increases across developed and developing regions, the addressable market for pet healthcare products and services expands, sustaining strong market growth.

Restraint:

High costs of pet healthcare services and products

The significant costs associated with veterinary care, prescription medications, and advanced treatments represent a major restraint for the pet healthcare market. Veterinary visits, diagnostic procedures, and surgical interventions require substantial financial commitment. Specialty care including oncology, cardiology, and advanced imaging is often prohibitively expensive. Pet owners may face difficult decisions about treatment affordability. Insurance coverage remains limited, particularly in developing regions. These cost barriers may limit access to quality pet healthcare, affecting market growth.

Opportunity:

Expansion of telemedicine and digital pet healthcare solutions

The growing adoption of telemedicine and digital health solutions for pets presents significant opportunities for market expansion. Telemedicine enables remote consultations, virtual follow-ups, and access to veterinary specialists regardless of geographic location. Digital health platforms support preventive care through reminders, wellness tracking, and educational resources. Integration with wearable devices enables continuous health monitoring. The COVID-19 pandemic accelerated telemedicine adoption, changing consumer expectations. As digital health technologies advance and acceptance grows, telemedicine and digital pet healthcare solutions capture growing market share, expanding the addressable market.

Threat:

Regulatory complexities and product approval challenges

The complex regulatory landscape governing veterinary pharmaceuticals and healthcare products poses significant threats to the pet healthcare market. Veterinary products require safety and efficacy approval from regulatory authorities, with varying requirements across jurisdictions. Approval processes can be lengthy and costly, delaying product launches. Generic competition may affect branded product profitability. Regulatory changes can affect existing approvals or require reformulation. These regulatory burdens may slow new product development and market entry, particularly for smaller companies with limited resources.

Covid-19 Impact:

The COVID-19 pandemic had a significant impact on the pet healthcare market. Pet adoption surged during lockdowns, expanding the pet population and creating new healthcare consumers. Veterinary practices adapted with telemedicine, curbside service, and enhanced infection control. Consumer focus on health and wellness extended to pets. E-commerce sales of pet healthcare products increased dramatically. Post-pandemic, elevated pet ownership levels and continued health awareness have sustained increased demand for pet healthcare, with the market experiencing continued growth.

The Oral segment is expected to be the largest during the forecast period

The Oral segment is expected to account for the largest market share during the forecast period, driven by the convenience, ease of administration, and high owner compliance associated with oral pet healthcare products. Oral administration includes tablets, chewables, liquids, and flavored formulations that are easily administered at home. The segment encompasses preventive treatments including heartworm preventives, flea and tick control, and nutritional supplements. The range of available products and established consumer familiarity support sustained demand. As pet owners seek convenient healthcare solutions, oral administration maintains the largest route segment share.

The Preventive Care segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Preventive Care segment is predicted to witness the highest growth rate, fueled by increasing awareness of the benefits of preventive healthcare, growing availability of preventive products, and shifting focus toward wellness management in veterinary medicine. Preventive care includes vaccines, parasite control, dental care, nutritional supplements, and regular health screenings. The segment benefits from veterinary recommendations emphasizing prevention over treatment. Growing pet insurance coverage supports preventive care adoption. As pet owners increasingly prioritize wellness and prevention, this segment delivers the fastest application growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by high pet ownership rates, strong spending on pet healthcare, and advanced veterinary healthcare infrastructure. The United States leads regional market growth with substantial investment in pet health. High awareness of preventive care and advanced treatment options among pet owners drives adoption. Strong presence of veterinary pharmaceutical and healthcare companies supports innovation. Established veterinary networks and specialist referral systems create consistent demand. With high pet spending and advanced infrastructure, North America maintains its dominant market position.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, driven by rising pet ownership, increasing disposable incomes, and growing awareness of pet healthcare across countries including China, India, Japan, and Southeast Asia. The region's rapidly growing pet population and expanding middle class create substantial demand for veterinary products and services. Veterinary practice modernization and technology adoption are accelerating. Growing awareness of preventive care and treatment options supports market expansion. Rising pet insurance adoption and e-commerce penetration increase accessibility. As pet healthcare develops, Asia Pacific delivers the fastest pet healthcare market growth globally.

Key players in the market

Some of the key players in Pet Healthcare Market include Zoetis Inc., Merck Animal Health, Elanco Animal Health Incorporated, Boehringer Ingelheim Animal Health, IDEXX Laboratories, Inc., Virbac S.A., Dechra Pharmaceuticals PLC, Ceva Sante Animale, Heska Corporation, Vetoquinol S.A., Covetrus, Inc., Neogen Corporation, BioChek B.V., BioNote, Inc., Bimeda, Inc., and Norbrook Laboratories Ltd.

Key Developments:

In June 2026, Elanco Animal Health announced plans to launch Elanco Ventures with a $25 million multi-year commitment, establishing a corporate venture capital platform dedicated to funding early-stage startups and accelerating innovation across therapeutics, digital tools, and One Health initiatives.

In May 2026, IDEXX Laboratories expanded its Fecal Dx antigen testing platform to include Taeniid tapeworm detection, enhancing non-invasive gastrointestinal parasite screening for veterinary practices.

In March 2026, Merck Animal Health received FDA approval for NUMELVI(TM) (atinvicitinib tablets), making it the first second-generation Janus Kinase (JAK) inhibitor for controlling pruritus associated with allergic dermatitis in dogs.

In January 2026, IDEXX Laboratories introduced a comprehensive diagnostic panel for canine mast cell tumors, advancing precision oncology and tailored treatment planning in veterinary medicine.

Products Covered:

• Therapeutics
• Diagnostics

Animal Types Covered:

• Dogs
• Cats
• Birds
• Horses
• Small Mammals
• Reptiles
• Fish
• Other Companion Animals

Therapeutic Areas Covered:

• Infectious Diseases
• Parasitic Diseases
• Dermatology
• Musculoskeletal Disorders
• Cardiology
• Oncology
• Endocrinology
• Gastrointestinal Disorders
• Respiratory Disorders
• Neurology
• Other Therapeutic Areas

Diagnostic Types Covered:

• Clinical Chemistry
• Hematology
• Immunodiagnostics
• Molecular Diagnostics
• Diagnostic Imaging
• Point-of-Care Testing
• Genetic Testing
• Microbiome Testing

Routes of Administration Covered:

• Oral
• Injectable
• Topical
• Transdermal
• Other Routes

Applications Covered:

• Preventive Care
• Disease Diagnosis
• Disease Treatment
• Wellness Management
• Rehabilitation and Recovery

End Users Covered:

• Veterinary Hospitals and Clinics
• Veterinary Diagnostic Laboratories
• Pet Owners
• Animal Shelters and Rescue Centers
• Research Institutes and Universities

Distribution Channels Covered:

• Veterinary Hospitals and Clinic Pharmacies
• Retail Pharmacies and Pet Stores
• E-Commerce
• Other Distribution Channels

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Pet Healthcare Market, By Product

• 5.1 Therapeutics
  • 5.1.1 Pharmaceuticals
  • 5.1.2 Biologics
  • 5.1.3 Nutraceuticals and Supplements
• 5.2 Diagnostics
  • 5.2.1 Instruments
  • 5.2.2 Consumables and Reagents
  • 5.2.3 Diagnostic Software and Services

6 Global Pet Healthcare Market, By Animal Type

• 6.1 Dogs
• 6.2 Cats
• 6.3 Birds
• 6.4 Horses
• 6.5 Small Mammals
• 6.6 Reptiles
• 6.7 Fish
• 6.8 Other Companion Animals

7 Global Pet Healthcare Market, By Therapeutic Area

• 7.1 Infectious Diseases
• 7.2 Parasitic Diseases
• 7.3 Dermatology
• 7.4 Musculoskeletal Disorders
• 7.5 Cardiology
• 7.6 Oncology
• 7.7 Endocrinology
• 7.8 Gastrointestinal Disorders
• 7.9 Respiratory Disorders
• 7.10 Neurology
• 7.11 Other Therapeutic Areas

8 Global Pet Healthcare Market, By Diagnostic Type

• 8.1 Clinical Chemistry
• 8.2 Hematology
• 8.3 Immunodiagnostics
• 8.4 Molecular Diagnostics
• 8.5 Diagnostic Imaging
  • 8.5.1 X-ray
  • 8.5.2 Ultrasound
  • 8.5.3 CT
  • 8.5.4 MRI
• 8.6 Point-of-Care Testing
• 8.7 Genetic Testing
• 8.8 Microbiome Testing

9 Global Pet Healthcare Market, By Route of Administration

• 9.1 Oral
• 9.2 Injectable
• 9.3 Topical
• 9.4 Transdermal
• 9.5 Other Routes

10 Global Pet Healthcare Market, By Application

• 10.1 Preventive Care
• 10.2 Disease Diagnosis
• 10.3 Disease Treatment
• 10.4 Wellness Management
• 10.5 Rehabilitation and Recovery

11 Global Pet Healthcare Market, By End User

• 11.1 Veterinary Hospitals and Clinics
• 11.2 Veterinary Diagnostic Laboratories
• 11.3 Pet Owners
• 11.4 Animal Shelters and Rescue Centers
• 11.5 Research Institutes and Universities

12 Global Pet Healthcare Market, By Distribution Channel

• 12.1 Veterinary Hospitals and Clinic Pharmacies
• 12.2 Retail Pharmacies and Pet Stores
• 12.3 E-Commerce
• 12.4 Other Distribution Channels

13 Global Pet Healthcare Market, By Geography

• 13.1 North America
  • 13.1.1 United States
  • 13.1.2 Canada
  • 13.1.3 Mexico
• 13.2 Europe
  • 13.2.1 United Kingdom
  • 13.2.2 Germany
  • 13.2.3 France
  • 13.2.4 Italy
  • 13.2.5 Spain
  • 13.2.6 Netherlands
  • 13.2.7 Belgium
  • 13.2.8 Sweden
  • 13.2.9 Switzerland
  • 13.2.10 Poland
  • 13.2.11 Rest of Europe
• 13.3 Asia Pacific
  • 13.3.1 China
  • 13.3.2 Japan
  • 13.3.3 India
  • 13.3.4 South Korea
  • 13.3.5 Australia
  • 13.3.6 Indonesia
  • 13.3.7 Thailand
  • 13.3.8 Malaysia
  • 13.3.9 Singapore
  • 13.3.10 Vietnam
  • 13.3.11 Rest of Asia Pacific
• 13.4 South America
  • 13.4.1 Brazil
  • 13.4.2 Argentina
  • 13.4.3 Colombia
  • 13.4.4 Chile
  • 13.4.5 Peru
  • 13.4.6 Rest of South America
• 13.5 Rest of the World (RoW)
  • 13.5.1 Middle East
    • 13.5.1.1 Saudi Arabia
    • 13.5.1.2 United Arab Emirates
    • 13.5.1.3 Qatar
    • 13.5.1.4 Israel
    • 13.5.1.5 Rest of Middle East
  • 13.5.2 Africa
    • 13.5.2.1 South Africa
    • 13.5.2.2 Egypt
    • 13.5.2.3 Morocco
    • 13.5.2.4 Rest of Africa

14 Strategic Market Intelligence

• 14.1 Industry Value Network and Supply Chain Assessment
• 14.2 White-Space and Opportunity Mapping
• 14.3 Product Evolution and Market Life Cycle Analysis
• 14.4 Channel, Distributor, and Go-to-Market Assessment

15 Industry Developments and Strategic Initiatives

• 15.1 Mergers and Acquisitions
• 15.2 Partnerships, Alliances, and Joint Ventures
• 15.3 New Product Launches and Certifications
• 15.4 Capacity Expansion and Investments
• 15.5 Other Strategic Initiatives

16 Company Profiles

• 16.1 Zoetis Inc.
• 16.2 Merck Animal Health
• 16.3 Elanco Animal Health Incorporated
• 16.4 Boehringer Ingelheim Animal Health
• 16.5 IDEXX Laboratories, Inc.
• 16.6 Virbac S.A.
• 16.7 Dechra Pharmaceuticals PLC
• 16.8 Ceva Sante Animale
• 16.9 Heska Corporation
• 16.10 Vetoquinol S.A.
• 16.11 Covetrus, Inc.
• 16.12 Neogen Corporation
• 16.13 BioChek B.V.
• 16.14 BioNote, Inc.
• 16.15 Bimeda, Inc.
• 16.16 Norbrook Laboratories Ltd.